The scientists at BSRC “Alexander Fleming” perform cutting-edge research, aiming to understand molecular mechanisms of complex biological processes in health and disease. We are also committed to contribute to innovation in medicine, by developing novel therapeutic and diagnostic methods, focusing on immunity and inflammation, cancer, and neurodegenerative diseases. To keep our focus on top-notch research, we recruit at all levels with excellence as the sole criterion and we support our researchers by providing state-of-the science infrastructures and a pleasant working environment. FLEMING is a non-profit organization operating under the auspices of the Greek General Secretariat for Research & Technology and is supported by the Greek government and by national, European and international grants.

Highlights

20/07/2017
20 July 2017

BSRC Fleming has signed a MoU with the National Bank of Greece sharing the common vision of fostering innovation and entrepreneurship in emerging areas of modern research. This partnership aims to contribute to the translation of scientific achievements into clinical practice and the development of innovative products of high added value. Press Release (in Greek).

12/05/2017
12 May 2017

Fleming researchers have identified two new dual inhibitors of TNF and RANKL, two key factors involved in inflammatory processes. These inhibitors can be further optimized to develop improved treatments for a range of inflammatory, autoimmune, and bone loss diseases (PubMed, Ηighlights in international press).

12/05/2017
12 May 2017

Work by Fleming researchers has revealed that omic profiles of synovial fibroblasts from the Tg197 human TNF-transgenic model of arthritis greatly mimic human synovial fibroblast profiles from Rheumatoid arthritis patients, revealing commonly represented pathways that may constitute potential targets for future therapies (Pubmed, Editorial)

20/04/2017
20 April 2017

Following a Forward Genetics approach, Fleming researchers identified a novel neurological mouse model caused by a functional mutation in the Slc25a46 gene, a new pathogenic target in a wide spectrum of human neurological diseases, including optic atrophy, Charcot-Marie-Tooth type 2, Leigh syndrome, progressive myoclonic ataxia and lethal congenital pontocerebellar hypoplasia. Pubmed

NEWS AND EVENTS

12/06/2017

2017/2018 Call for Applications.
The National and Kapodistrian University of Athens in collaboration with BSRC 'Alexander Fleming' organize the International MSc Program in MOLECULAR BIOMEDICINE.

WebMail

For internal users

B.S.R.C. "Alexander Fleming"
34 Fleming Street, 16672 Vari, Greece
Contact us